MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa, E.
Right arrow Articles by Guidotti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa, E.
Right arrow Articles by Guidotti, A.
Molecular Interventions 3:220-229 (2003)
© 2003 American Society of Pharmacology and Experimental Therapeutics

Review

Epigenetic Downregulation of GABAergic Function in Schizophrenia: Potential for Pharmacological Intervention?

Erminio Costa, Dennis R. Grayson and Alessandro Guidotti

The Psychiatric Institute, Department of Psychiatry University of Illinois at Chicago, Chicago, IL

Correspondence: Send correspondence to EC. E-mail costa{at}psych.uic.edu; fax 312-413-4569.


Although the propensity to develop schizophrenia has long been attributed in part to a "genetic" component, this component does not follow Mendelian laws and may be primarily epigenetic. We have detected a decrease in levels of mRNA encoding the 67-kDa glutamate decarboxylase (GAD67), but not of that encoding GAD65, in several cortical areas from the brains of patients afflicted with either schizophrenia or bipolar disorder, but not from patients with severe depression. In addition, dendritic levels of reelin (and the mRNA that encodes it), a protein essential to neurodevelopment, are decreased in schizophrenia. We have further investigated whether hypermethylation of the genes that encode the GADs and reelin might be at the root of the observed decreases in corresponding mRNA. Indeed, administration of methionine, a source of methyl groups in multiple enzymatic reactions, causes a recrudescence of schizophrenic symptoms, and we have correlated high intake of methionine in mice with both an increase in levels of promoter methylation and a decrease in production of reelin and GAD67. This decrease is reversed by treatment with valproate, an inhibitor of histone deacetylase.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
F. M. Benes, B. Lim, D. Matzilevich, J. P. Walsh, S. Subburaju, and M. Minns
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
PNAS, June 12, 2007; 104(24): 10164 - 10169.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Iwamoto, M. Bundo, K. Yamada, H. Takao, Y. Iwayama-Shigeno, T. Yoshikawa, and T. Kato
DNA Methylation Status of SOX10 Correlates with Its Downregulation and Oligodendrocyte Dysfunction in Schizophrenia
J. Neurosci., June 1, 2005; 25(22): 5376 - 5381.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Veldic, H. J. Caruncho, W. S. Liu, J. Davis, R. Satta, D. R. Grayson, A. Guidotti, and E. Costa
DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains
PNAS, January 6, 2004; 101(1): 348 - 353.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.